Skip to main content

Table 5 Comparison of the occurrence of safety end points in patients treated with and without mild therapeutic hypothermia

From: ACS network-based implementation of therapeutic hypothermia for the treatment of comatose out-of-hospital cardiac arrest survivors improves clinical outcomes: the first European experience

  Patients undergoing MTH procedure Control group p
  (n = 32) (n = 33)  
Definite stent thrombosis* 0 (0%) 0 (0%) ns
Probable stent thrombosis* 0 (0%) 2 (7.4%) ns
Pneumonia 19 (59.4%) 19 (57.6%) ns
Positive blood culture 12 (37.5%) 11 (33.3%) ns
Bleeding of any severity 8 (25.0%) 5 (15.2%) ns
Red blood cell transfusion 4 (12.5%) 2 (6.1%) ns
Rhythm and conductions disorders:    ns
  Atrial fibrillation 6 (18.8%) 7 (21.2%)
  Ventricular tachycardia 3 (9.4%) 1 (3.0%) ns
  Clinically relevant bradycardia 3 (9.4%) 1 (3.0%) ns
  1. * The percentage refers to the number of patients treated with percutaneous coronary intervention in the group. MTH Mild therapeutic hypothermia.